GSK reports sales and profit growth to start 2025
GSK plc announced a strong start to 2025 with first-quarter sales reaching £7.5 billion, up 2% on a constant exchange rate basis. The company also secured two new drug approvals anticipated for this year.
Pharmaceutical group GSK plc released its first-quarter results on April 30, 2025, reporting growth in both sales and profits. The company's total sales reached £7.5 billion, a 2% increase on a constant exchange rate (CER) basis compared to the previous year.
Sales of Specialty Medicines saw a significant increase, reaching £2.9 billion, representing a 17% rise. This growth was driven by strong performance in Respiratory, Immunology, and Oncology medicines, which saw increases of 28%, and 53% respectively, alongside a 7% rise in HIV sales. Vaccine sales declined by 6% to £2.1 billion, partly due to a decrease in sales of Shingrix (-7%) and Arexvy (-57%), although meningitis vaccines saw a 20% increase.
The total operating profit increased by 50%, and total earnings per share (EPS) by 56%. The company attributed this performance to the robust results from Specialty Medicines and disciplined investment in research and development. GSK is anticipating five major new product approvals from the US Food and Drug Administration (FDA) in 2025, two of which were secured in the first quarter.
GSK reaffirmed its full-year guidance for 2025, expecting turnover growth of 3% to 5%, and core operating profit and core EPS growth of 6% to 8%. The company has also continued with share buybacks and dividend declarations as part of its strategy to ensure long-term growth prospects and shareholder returns.